Tresiba is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Insulin Degludec.
| Product ID | 0169-2660_b7aeb64e-5f1b-458e-ae42-e89ba622a60a |
| NDC | 0169-2660 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Tresiba |
| Generic Name | Insulin Degludec Injection |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2015-09-25 |
| Marketing Category | BLA / NDA |
| Application Number | BLA203314 |
| Labeler Name | Novo Nordisk |
| Substance Name | INSULIN DEGLUDEC |
| Active Ingredient Strength | 100 U/mL |
| Pharm Classes | Insulin [CS],Insulin Analog [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2015-09-25 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA203314 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2015-09-25 |
| Marketing Category | NDA |
| Application Number | NDA203314 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2015-09-25 |
| Marketing Category | NDA |
| Application Number | NDA203314 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2019-11-20 |
| Ingredient | Strength |
|---|---|
| INSULIN DEGLUDEC | 100 U/mL |
| SPL SET ID: | 456c5e87-3dfd-46fa-8ac0-c6128d4c97c6 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0169-2550 | Tresiba | insulin degludec injection |
| 0169-2660 | Tresiba | insulin degludec injection |
| 0169-2662 | Tresiba | insulin degludec injection |
| 50090-3491 | Tresiba | insulin degludec |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() TRESIBA 79080004 3841743 Live/Registered |
Novo Nordisk A/S 2010-02-03 |